AUPR783601A0 - Prognostic method - Google Patents

Prognostic method

Info

Publication number
AUPR783601A0
AUPR783601A0 AUPR7836A AUPR783601A AUPR783601A0 AU PR783601 A0 AUPR783601 A0 AU PR783601A0 AU PR7836 A AUPR7836 A AU PR7836A AU PR783601 A AUPR783601 A AU PR783601A AU PR783601 A0 AUPR783601 A0 AU PR783601A0
Authority
AU
Australia
Prior art keywords
prognostic method
prognostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR7836A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Melbourne filed Critical University of Melbourne
Priority to AUPR7836A priority Critical patent/AUPR783601A0/en
Publication of AUPR783601A0 publication Critical patent/AUPR783601A0/en
Priority to PCT/AU2002/001293 priority patent/WO2003025217A1/en
Priority to AU2002328676A priority patent/AU2002328676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
AUPR7836A 2001-09-20 2001-09-20 Prognostic method Abandoned AUPR783601A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPR7836A AUPR783601A0 (en) 2001-09-20 2001-09-20 Prognostic method
PCT/AU2002/001293 WO2003025217A1 (en) 2001-09-20 2002-09-20 Prognostic method
AU2002328676A AU2002328676A1 (en) 2001-09-20 2002-09-20 Prognostic method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR7836A AUPR783601A0 (en) 2001-09-20 2001-09-20 Prognostic method

Publications (1)

Publication Number Publication Date
AUPR783601A0 true AUPR783601A0 (en) 2001-10-18

Family

ID=3831676

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPR7836A Abandoned AUPR783601A0 (en) 2001-09-20 2001-09-20 Prognostic method
AU2002328676A Abandoned AU2002328676A1 (en) 2001-09-20 2002-09-20 Prognostic method

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002328676A Abandoned AU2002328676A1 (en) 2001-09-20 2002-09-20 Prognostic method

Country Status (2)

Country Link
AU (2) AUPR783601A0 (en)
WO (1) WO2003025217A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904649A2 (en) * 2005-07-18 2008-04-02 Epigenomics AG Compositions and methods for cancer diagnostics comprising pan-cancer markers
US11118182B2 (en) 2016-11-17 2021-09-14 Ramot At Tel-Aviv University Ltd. Modulators of human KAI1 metastasis suppressor gene, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204000B1 (en) * 1995-04-28 2001-03-20 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
WO2000014234A1 (en) * 1998-09-08 2000-03-16 Urocor, Inc. Prostate specific promoter and regulation of gene expression

Also Published As

Publication number Publication date
WO2003025217A8 (en) 2003-05-08
AU2002328676A1 (en) 2003-04-01
WO2003025217A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU2002249467A1 (en) Screening method
WO2002059807A8 (en) Data anlysis method
AU2002341150A1 (en) Method
AUPR966701A0 (en) Identification method
AU2002309621A1 (en) Predictive method
AU2002301014A1 (en) Reacting method
AUPR772601A0 (en) Transaction method
AUPR633101A0 (en) Method
AU2002328676A1 (en) Prognostic method
AU2002354247A1 (en) Screening method
AU2002308561A1 (en) Selection method
AUPR702301A0 (en) Assembly method for pivot assembly
AU2002311155A1 (en) Dry-etcching method
AU2002249473A1 (en) Method
AU2002249345A1 (en) Method
AUPR858501A0 (en) Impregnational method
AU2002304420A1 (en) Novel method
AU2002251479A1 (en) Drawing method
AU2002242668A1 (en) Method for rock-chiseling
AU2001252688A1 (en) Information providing method
AUPR517901A0 (en) Selection method
AU2002251478A1 (en) Rendering method
AU2002305049A1 (en) Application development method
AU2002253641A1 (en) Immunoassay method
AU2002251392A1 (en) Mining method